Adam Bubes

George Notter

Scott Searle

- **CORRIDOR**, a product line of CAMP Systems, has deployed its **AI Operations Manager** with **ACI Jet** following a successful pilot program.  **[1736730_71ed4c50c5214edb92f17cf0d31cacf8_0]** 
- The **AI Operations Manager** applies predictive intelligence to modernize maintenance planning and execution, aiming to enhance accuracy, efficiency, and profitability for service centers and MROs.  **[1736730_71ed4c50c5214edb92f17cf0d31cacf8_0]** 
- Early deployments have demonstrated measurable results, including up to **10% faster sales cycles**, a **50% reduction in unpaid work**, and cost savings of up to **20%** through improved mechanic efficiency and optimized material planning.  **[1736730_71ed4c50c5214edb92f17cf0d31cacf8_0]** 
- **ACI Jet** confirmed that this technology is already creating a measurable impact across their operations by anticipating labor and parts needs, reducing variability, and improving turnaround times.  **[1736730_71ed4c50c5214edb92f17cf0d31cacf8_0]**

CAMP's CORRIDOR Advances AI Operations Manager to Production

- CAMP4 Therapeutics Corporation has **initiated GLP toxicology studies** for its lead product candidate, **CMP-SYNGAP-01**, as of October 1, 2025.  **[1736730_0001736730-25-000074_a20251001exhibit991.htm:0]** 
- These studies are a critical step towards a planned clinical trial application, which could enable the initiation of a **first-in-human Phase 1/2 clinical trial** for SYNGAP1-related disorders as early as the **second half of 2026**.  **[1736730_0001736730-25-000074_a20251001exhibit991.htm:0]** 
- CMP-SYNGAP-01 is an investigational therapeutic designed to upregulate SYNGAP1 gene expression to restore SYNGAP protein levels, addressing SYNGAP1-related disorders for which there are **no FDA-approved disease-modifying therapies**.  **[1736730_0001736730-25-000074_a20251001exhibit991.htm:0]** 
- Preclinical studies have demonstrated **robust activity** for CMP-SYNGAP-01, including restoring SYNGAP1 protein levels in a mouse model and increasing SYNGAP1 protein in non-human primate brain regions.  **[1736730_0001736730-25-000074_a20251001exhibit991.htm:0]**

Camp4 Therapeutics (CAMP)